Slide 1: FY17 Financial Results
For personal use only FY17 Financial Results August 2017 © 2016 Cogstate Ltd. All rights reserved.
Slide 2: Corporate Overview
CORPORATE OVERVIEW Strong conviction from long-term shareholders has enabled Cogstate to develop a For personal use only unique technology platform, extensive validation and expanding supporting services. Highly credentialed and well aligned Board and Trading information management team holding >40%
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS A world-class cognitive science, technology and services company focused on For personal use only optimising and monetising the measurement of cognition. ▪ Continued growth in Clinical Trials revenue and profit; revenue up 28% resulting in profit contribution of A$19 million ▪
Slide 4: Expanded Solutions
EXPANDED SOLUTIONS Focus on continued growth; Expanded solutions to meet current and future needs For personal use only of customers. ▪ Enhancements to computerised tests of cognition; scalable and decentralised, with potential for home-based assessment ▪ Completely reengineered how traditional test
Slide 5: Experience and Expertise
EXPERIENCE AND EXPERTISE Extremely well qualified non-executive directors; Management team with deep For personal use only industry knowledge. ▪ Richard Mohs; independent non-executive director with extensive academic and industry experience, most recently at Eli Lilly & Co. ▪ Jane McAloon; independ
Slide 6: Clinical Trials Profit Contribution
CLINICAL TRIALS PROFIT CONTRIBUTION Clinical Trials Profit Contribution ! For personal use only 40,000,000 34,652,048 35,000,000 30,000,000 27,140,935 25,000,000 19,092,047 20,000,000 AUD $ 15,702,044 15,775,169 15,000,000 11,313,323 10,779,519 9,060,945 10,000,000 6,521,790 6,175,860 5,000,000 0 20
Slide 7: Investments for Growth
INVESTMENTS FOR GROWTH Investments to facilitate continued future growth both within the Clinical Trials For personal use only segment as well as new markets. FY17 FY16 Healthcare ($1.23m) ($0.97m) - preparation for FDA submission and commercial launch of Cognigram R&D ($0.75m) ($0.56m) - validating
Slide 8: Net Cash Inflow from Operations
NET CASH INFLOW FROM OPERATIONS Cash reserves at 30 June 2017: A$9.3m, an increase of A$1.8m during the year. For personal use only Non-cash expenses: Depreciation A$1.0m (FY16 A$0.9m) Share based payments A$1.0m (FY16 A$0.2m) Unrealised foreign exchange loss A$0.4m (FY16 A$0.2m) The increase in sha
Slide 9: Key Future Developments
KEY FUTURE DEVELOPMENTS Looking ahead to the 2018 financial year, Cogstate are well placed for For personal use only considerable growth and development. ▪ Change in functional reporting currency to US$ ▪ Increase in Clinical Trial sales, driven by more than 100% growth in sales pipeline ▪ Increased
Slide 10: Cogstate
COGSTATE Cognition disorders A|Zheimer's disea S@ Heart failure Major depressive disorder muttipte sclerosis (Ms) Hepatitis C Parkinson's disease Diabetic peripheral neuropathy Mild cognitive impairment Insomnia Sch izo p h ren ia Overactive bladder Stroke Obsessive compulsive disorder Alcohol Toxic